U.S., Aug. 21 -- ClinicalTrials.gov registry received information related to the study (NCT07132398) titled 'Slow vs. Rapid Glucocorticoids Tapering With Inebilizumab in NMOSD' on June 17.
Brief Summary: Neuromyelitis optica spectrum disorder (NMOSD) is a central nervous system autoimmune condition mainly involving the spinal cord, optic nerves, and area postrema. The anti-aquaporin-4 (AQP4)-Immunoglobulin G (IgG) is a specific biomarker for NMOSD. Glucocorticoids(GCs) are used as first-line treatment for NMOSD. Oral glucocorticoids tapering is always suggested following the pused therapy in the maintenance phase. Inebilizumab, a humanized monoclonal antibody targeting CD19, has been proven effective in preventing NMOSD relapses. This stud...